Open access · CC-BY
via OpenAlex
A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
Junjie Hu, Bei Liu, Wangxiong Hu, Yanmei Yang
Heliyon · 2022 · ▲ 3 citations
Abstract
Identifying indicators of immunotherapy response are key to clinical treatment decisions. To date, immunotherapy is most widely used in melanoma because of its higher tumor mutation burden compared to other cancer types. However, less than half of melanoma patients can benefit from immune checkpoint inhibitor (ICI) therapy. For this reason, we deciphered pretreatment transcriptomes across a cohort of melanoma patients receiving anti-PD-1 or CTLA-4 alone (sICI) or in combination (cICI). We developed a two-gene signature that could predict the curative effect of ICI in melanoma by using the LASSO method. The pre-ICI signature displayed an equally competitive predictive power as the post-ICI irRECIST assessment that could offer clues regarding long-term ICI therapy response and facilitate risk stratification and treatment strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.heliyon.2022.e12648
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Hu, J., Liu, B., Hu, W., & Yang, Y. (2022). A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma. <em>Heliyon</em>. https://doi.org/10.1016/j.heliyon.2022.e12648
Vancouver
Hu J, Liu B, Hu W, Yang Y. A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma. Heliyon. 2022. doi:10.1016/j.heliyon.2022.e12648.
BibTeX
@article{junjie2022Apretr,
title = {A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma},
author = {Junjie Hu and Bei Liu and Wangxiong Hu and Yanmei Yang},
journal = {Heliyon},
year = {2022},
doi = {10.1016/j.heliyon.2022.e12648},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Osteoporosis International 2024
Citation only
Gut microbiome and bone health: update on mechanisms, clinical correlations, and possible treatment strategies
Journal of Thoracic Oncology 2019
Open access · OA
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
Nature Medicine 2022
Open access · CC-BY
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
International Journal of Molecular Sciences 2022
Open access · CC-BY
Intravenous Nicotinamide Riboside Administration Has a Cardioprotective Effect in Chronic Doxorubicin-Induced Cardiomyopathy
Royal Marsden NHS Foundation Trust 2020
Open access · US-GOV
Feasibility of Frailty Assessment and Implementation of Protocol-led Geriatric Interventions in Women Over the Age of 70 With Epithelial Ovarian Cancer in the Oncology Clinic (FAIR-O)
Journal for ImmunoTherapy of Cancer 2019
Open access · CC-BY